Sinovac, the Chinese pharmaceutical that makes CoronaVac, will begin clinical trials to adapt the Covid-19 vaccine to the new Ômicron variant. The initiative was announced this Tuesday (7), at an event held by the Butantan Institute in São Paulo.
Vice President of Sinovac, Yaling Hu said that tests of the updated version of the Chinese immunizing agent should be completed in three months.
+ CoronaVac has been working against Ômicron, says president of Sinovac
+ Initial indications suggest Ômicron is more transmissible than Delta, British prime minister tells ministers
The company’s CEO, Weidong Yin, pointed out that the current version of CoronaVac is effective in combating the new strain of coronavirus. “The vaccine has proven effective against this variant (Ômicron) and we are developing a new immunizer based on the variant.”
“We are going to announce studies with a range of variants”, declared the president of the Butantan Institute, Dimas Covas.
The Ministry of Health did not make new acquisitions of CoronaVac from the National Immunization Program (PNI) after the first 100 million doses, under the argument that the immunizing agent does not have a definitive registration with the National Health Surveillance Agency (Anvisa). CoronaVac is authorized for emergency use only.
Sinovac post announces testing phase to update CoronaVac against Ômicron first appeared in ISTOÉ MONEY.
#Sinovac #announces #testing #phase #update #CoronaVac #Ômicron